Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-HAIC + sindilizumab + bevacizumab analogue as first-line therapy for unresectable hepatocellular carcinoma
ChiCTR2500102206Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Gannan Medical University
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sindilizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Gannan Medical University. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
sindilizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500102206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102206.